Drugs / LCZ
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06236061 Comparator | Apr 2024 → May 2025 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LCZ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06236061 ↗ |
| Route | Oral | “Oral administration, 1 tablet of LCZ 200 mg daily” NCT06236061 ↗ |